Startup | August 20, 2021
Navia Life Care raises US $ 1 million in Series A funding
The company plans to invest in technology, business development, product innovation, and development across India
The company plans to invest in technology, business development, product innovation, and development across India
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
Kauvery group of hospitals, a leading healthcare chain in Tamil Nadu, has roped in former Indian cricket captain Mahendra Singh Dhoni as its brand ambassador
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Subscribe To Our Newsletter & Stay Updated
